Tenaya Therapeutics, Inc.: net property, plant and equipment

What this measure means

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Tenaya Therapeutics, Inc.: total assets
• Tenaya Therapeutics, Inc.: total liabilities
• Tenaya Therapeutics, Inc.: stockholders equity
• Tenaya Therapeutics, Inc.: cash and cash equivalents
• Tenaya Therapeutics, Inc.: net income or loss
• Tenaya Therapeutics, Inc.: operating cash flow
• Tenaya Therapeutics, Inc.: capital expenditure payments
• Tenaya Therapeutics, Inc.: financing cash flow
• Tenaya Therapeutics, Inc.: investing cash flow
• Tenaya Therapeutics, Inc.: retained earnings or deficit
• Tenaya Therapeutics, Inc.: basic weighted-average shares
• Tenaya Therapeutics, Inc.: diluted weighted-average shares
• Tenaya Therapeutics, Inc.: basic earnings per share
• Tenaya Therapeutics, Inc.: diluted earnings per share
• Tenaya Therapeutics, Inc.: share-based compensation expense
• Tenaya Therapeutics, Inc.: operating income or loss
• Tenaya Therapeutics, Inc.: current assets
• Tenaya Therapeutics, Inc.: current liabilities
• Tenaya Therapeutics, Inc.: current accounts payable
• Tenaya Therapeutics, Inc.: operating expenses
• Tenaya Therapeutics, Inc.: research and development expense
• Tenaya Therapeutics, Inc.: common shares outstanding
• Tenaya Therapeutics, Inc.: cash including restricted cash
• Tenaya Therapeutics, Inc.: additional paid-in capital
• Tenaya Therapeutics, Inc.: accumulated other comprehensive income or loss
• Tenaya Therapeutics, Inc.: operating lease right-of-use asset
• Tenaya Therapeutics, Inc.: operating lease liability
• Tenaya Therapeutics, Inc.: gross property, plant and equipment
• Tenaya Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Tenaya Therapeutics, Inc.: other noncurrent assets
• Tenaya Therapeutics, Inc.: other noncurrent liabilities
• Tenaya Therapeutics, Inc.: accrued current liabilities
• Tenaya Therapeutics, Inc.: prepaid expenses and other current assets
• Tenaya Therapeutics, Inc.: net deferred tax assets
• Tenaya Therapeutics, Inc.: pre-tax income or loss from continuing operations
• Tenaya Therapeutics, Inc.: profit or loss including noncontrolling interests
• Tenaya Therapeutics, Inc.: comprehensive income or loss
• Tenaya Therapeutics, Inc.: general and administrative expense
• Tenaya Therapeutics, Inc.: depreciation, depletion and amortization
• Tenaya Therapeutics, Inc.: other nonoperating income or expense
• Tenaya Therapeutics, Inc.: nonoperating income or expense
• Tenaya Therapeutics, Inc.: operating lease payments
• Tenaya Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Tenaya Therapeutics, Inc. / CIK 0001858848

Captured

2026-09-21T17:33:09.643Z

SEC response SHA-256

8c0c2d88cb093609725b250d0cd55ebce41b67e41d3b2a73038b34021f7a1555

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001858848.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))